Vanda Pharmaceuticals (VNDA) Other Gross PP&E Adjustments (2011 - 2026)

Vanda Pharmaceuticals has disclosed Other Gross PP&E Adjustments across 16 years of filings, most recently posting -$13.2 million for Q1 2026.

• Other Gross PP&E Adjustments for Q1 2026 came in at -$13.2 million, down 26.59% year-over-year; the trailing twelve-month figure through Mar 2026 was -$13.2 million (down 26.59% YoY), and the FY2025 annual result was $7.5 million, down 7.11% from the prior year.
• Other Gross PP&E Adjustments came in at -$13.2 million for Q1 2026 at Vanda Pharmaceuticals, down from $7.5 million in the prior quarter.
• In the past five years, Other Gross PP&E Adjustments ranged from a high of $8.1 million in Q4 2024 to a low of -$13.2 million in Q1 2026.
• The 5-year median for Other Gross PP&E Adjustments is -$8.5 million (2023), against an average of -$5.6 million.
• Across the five-year window, Other Gross PP&E Adjustments surged 42.7% in 2022 and retreated 29.92% in 2024, its largest moves.
• Vanda Pharmaceuticals' Other Gross PP&E Adjustments stood at $4.6 million in 2022, then jumped by 33.17% to $6.1 million in 2023, then surged by 32.41% to $8.1 million in 2024, then declined by 7.11% to $7.5 million in 2025, then plunged by 276.11% to -$13.2 million in 2026.
• The last three Other Gross PP&E Adjustments figures came in at -$13.2 million (Q1 2026), $7.5 million (Q4 2025), and -$6.1 million (Q3 2025), per Business Quant data.